Delafloxacin meglumine Drug Asset Due Diligence Report 2026

This Delafloxacin meglumine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Delafloxacin meglumine can convert its Small molecule drug profile and Bacterial Top II x Bacterial top IV biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Delafloxacin meglumine (query alias: delafloxacin)
Modality / target	Small molecule drug; Bacterial Top II x Bacterial top IV; Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors
Highest global status	Approved
Originator	Wakunaga Pharmaceutical Co., Ltd.
Active developers	A.Menarini Industrie Farmaceutiche Riunite Srl, Xediton Pharmaceuticals, Inc.

The MCP disease footprint includes Bacterial Infections, Community Acquired Pneumonia, Skin and skin structure infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05977868	Phase 4	Terminated	94	Cure/Control at 3 Months
CTR20242620	Phase 1	进行中（尚未招募）	60	Not disclosed
NCT06612255	Phase 1	Terminated	16	Area Under the Mean Concentration Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Delafloxacin Powder Compared to Oral Delafloxacin Tablet

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 1, Single Part, Partially Randomised, Open-Label Study to Evaluate the Relative Bioavailability of a Taste-Masked Delafloxacin Powder for Oral Suspension With Oral Delafloxacin Tablet Reference in Healthy Subjects

Phase 1; n=16; evaluation: not stated. Reported fields: Area Under the Mean Concentration Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Delafloxacin Powder Compared to Oral Delafloxacin Tablet(Geometric Mean): Fixed Effect Analysis = 51.68(90% CI, 45.71 - 58.43); Area Under the Mean Concentration Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Delafloxacin Powder Compared to Oral Delafloxacin Tablet(Geometric Mean) = 15700 ng*h/mL (Geometric Coefficient of Variation, 26.9); Area Under the Mean Concentration Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Delafloxacin Powder Compared to Oral Delafloxacin Tablet(Geometric Mean): Fixed Effect Analysis = 51.68(90% CI, 45.71 - 58.43)

A Randomized, Observer-Blinded, Active-Controlled, Phase IIIb Study to Compare IV/Oral Delafloxacin Fixed-Dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections: The DRESS Study

Phase 3; n=266; evaluation: Positive. Reported fields: Microbiological response = 79.4 % ; Microbiological response = 89.5 %

Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial

Phase 4; n=94; evaluation: not stated. Reported fields: -; Cure/Control at 3 Months = 28 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Delafloxacin meglumine addresses Bacterial Infections, Community Acquired Pneumonia, Skin and skin structure infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-08-07	CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team	Approved	US$300.0M upfront; US$25.0M milestones; US$325.0M stated total
2023-07-10	Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens	Approved	Financial terms not disclosed
2023-05-15	Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising delafloxacin for administration into the lung”. The milestone feed surfaced a patent-application signal described as “Method for refining delafloxacin and intermediate thereof”. The milestone feed surfaced a patent-application signal described as “Refining method for delafloxacin and meglumine salt thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO